Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Ltd.

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

remains one of the most challenging and devastating cancers, with low survival rates and few effective treatment optio...
01/02/2026

remains one of the most challenging and devastating cancers, with low survival rates and few effective treatment options.

At , we believe advancing innovative research is essential to improving outcomes and bringing new hope to patients.

Wishing you a Happy New Year!Here's to a 2026 filled with progress, innovation and new possibilities in oncology.
12/31/2025

Wishing you a Happy New Year!

Here's to a 2026 filled with progress, innovation and new possibilities in oncology.

Happy Holidays from Xenetic Bio!Wishing you a season filled with health, hope and gratitude.
12/23/2025

Happy Holidays from Xenetic Bio!

Wishing you a season filled with health, hope and gratitude.

1.7 million people in the U.S. are diagnosed with solid tumors each year, highlighting the urgent need for new and effec...
12/19/2025

1.7 million people in the U.S. are diagnosed with solid tumors each year, highlighting the urgent need for new and effective therapeutic approaches.

At , we’re committed to advancing innovation in oncology.

We are a biopharmaceutical company dedicated to advancing our proprietary technology platforms to address multiple high-...
12/15/2025

We are a biopharmaceutical company dedicated to advancing our proprietary technology platforms to address multiple high-value cancer indications and unlock new possibilities in oncology.

We remain focused on advancing our development strategy through strong institutional partnerships.If you’re interested i...
12/09/2025

We remain focused on advancing our development strategy through strong institutional partnerships.

If you’re interested in collaborating with Xenetic Bio, please reach out to us at info@xeneticbio.com

Our lead program has the potential to elevate current cancer treatment approaches and advance options for patients. Lear...
12/04/2025

Our lead program has the potential to elevate current cancer treatment approaches and advance options for patients.

Learn more: https://bit.ly/48kraJS

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research...
11/19/2025

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

https://bit.ly/4pmRTNd

Our lead program aims to overcome T cell exclusion and immunosuppressive signals in the tumor microenvironment, unlockin...
11/18/2025

Our lead program aims to overcome T cell exclusion and immunosuppressive signals in the tumor microenvironment, unlocking new possibilities in cancer treatment and bringing hope to patients who need it most.

: Early detection of remains a major challenge. Most patients are diagnosed at advanced stages, leading to a five-yea...
11/10/2025

: Early detection of remains a major challenge. Most patients are diagnosed at advanced stages, leading to a five-year survival rate of only about 3%. We’re working to help change that.

Address

40 Speen Street
Framingham, MA
01701

Telephone

+17817787720

Website

Alerts

Be the first to know and let us send you an email when Xenetic Biosciences, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Xenetic Biosciences, Inc.:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.